Table: q1_q4_2021_prescription_drug_wac_increases , manufacturer_name like N*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000106	Neos Therapeutics, Inc.	03/31/2021	70165002030	Adzenys XR-ODT Oral Tablet Extended Release Disintegrating 12.5 MG	01/09/2021	39.60	435.60	06/28/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Please note that California has stated that in their review of the WAC that an increase took place on December 31, 2018 vs. January 1, 2019, as indicated by Neos Therapeutics. Please note that the increase actually took place on 1/1/2019, however there was an issue with one of the databanks loading it early. This is an issue with the databank and Neos has been working with the Databank in attempt to get the issue resolved. All of the acquisition related fields were left blank as Neos is the “original” marketer of this product and it was not acquired from another manufacturer.
Rx0000106	Neos Therapeutics, Inc.	03/31/2021	70165002530	Adzenys XR-ODT Oral Tablet Extended Release Disintegrating 15.7 MG	01/09/2021	39.60	435.60	06/28/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Please note that California has stated that in their review of the WAC that an increase took place on December 31, 2018 vs. January 1, 2019, as indicated by Neos Therapeutics. Please note that the increase actually took place on 1/1/2019, however there was an issue with one of the databanks loading it early. This is an issue with the databank and Neos has been working with the Databank in attempt to get the issue resolved. All of the acquisition related fields were left blank as Neos is the “original” marketer of this product and it was not acquired from another manufacturer.
Rx0000106	Neos Therapeutics, Inc.	03/31/2021	70165003030	Adzenys XR-ODT Oral Tablet Extended Release Disintegrating 18.8 MG	01/09/2021	39.60	435.60	06/28/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Please note that California has stated that in their review of the WAC that an increase took place on December 31, 2018 vs. January 1, 2019, as indicated by Neos Therapeutics. Please note that the increase actually took place on 1/1/2019, however there was an issue with one of the databanks loading it early. This is an issue with the databank and Neos has been working with the Databank in attempt to get the issue resolved. All of the acquisition related fields were left blank as Neos is the “original” marketer of this product and it was not acquired from another manufacturer.
Rx0000106	Neos Therapeutics, Inc.	03/31/2021	70165000530	Adzenys XR-ODT Oral Tablet Extended Release Disintegrating 3.1 MG	01/09/2021	39.60	435.60	06/28/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Please note that California has stated that in their review of the WAC that an increase took place on December 31, 2018 vs. January 1, 2019, as indicated by Neos Therapeutics. Please note that the increase actually took place on 1/1/2019, however there was an issue with one of the databanks loading it early. This is an issue with the databank and Neos has been working with the Databank in attempt to get the issue resolved. All of the acquisition related fields were left blank as Neos is the “original” marketer of this product and it was not acquired from another manufacturer.
Rx0000106	Neos Therapeutics, Inc.	03/31/2021	70165001030	Adzenys XR-ODT Oral Tablet Extended Release Disintegrating 6.3 MG	01/09/2021	39.60	435.60	06/28/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Please note that California has stated that in their review of the WAC that an increase took place on December 31, 2018 vs. January 1, 2019, as indicated by Neos Therapeutics. Please note that the increase actually took place on 1/1/2019, however there was an issue with one of the databanks loading it early. This is an issue with the databank and Neos has been working with the Databank in attempt to get the issue resolved. All of the acquisition related fields were left blank as Neos is the “original” marketer of this product and it was not acquired from another manufacturer.
Rx0000106	Neos Therapeutics, Inc.	03/31/2021	70165001530	Adzenys XR-ODT Oral Tablet Extended Release Disintegrating 9.4 MG	01/09/2021	39.60	435.60	06/28/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Please note that California has stated that in their review of the WAC that an increase took place on December 31, 2018 vs. January 1, 2019, as indicated by Neos Therapeutics. Please note that the increase actually took place on 1/1/2019, however there was an issue with one of the databanks loading it early. This is an issue with the databank and Neos has been working with the Databank in attempt to get the issue resolved. All of the acquisition related fields were left blank as Neos is the “original” marketer of this product and it was not acquired from another manufacturer.
Rx0000106	Neos Therapeutics, Inc.	03/31/2021	70165020030	COTEMPLA XR-ODT 17.3MG 30 Tabs/Bottle	01/09/2021	25.20	445.20	06/28/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All of the acquisition related fields were left blank as Neos is the “original” marketer of this product and it was not acquired from another manufacturer.
Rx0000106	Neos Therapeutics, Inc.	03/31/2021	70165030030	COTEMPLA XR-ODT 25.9MG 30 Tabs/Bottle	01/09/2021	25.20	445.20	06/28/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All of the acquisition related fields were left blank as Neos is the “original” marketer of this product and it was not acquired from another manufacturer.
Rx0000106	Neos Therapeutics, Inc.	03/31/2021	70165010030	COTEMPLA XR-ODT 8.6MG, 30 Tabs/Bottle	01/09/2021	25.20	445.20	06/28/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All of the acquisition related fields were left blank as Neos is the “original” marketer of this product and it was not acquired from another manufacturer.
Rx0000418	Nexus Pharmaceuticals, Inc.	12/31/2021	14789090110	Procainamide HCL 100mg 10mL pack of 10	10/18/2021	1056.30	3000.00	None	Non-innovator Multiple Source Drug	6270	None	Nexus considers multiple factors in determining ongoing pricing of their prescription drugs including value provided to patients, patient populations and changing market and competitive conditions.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000420	Nielsen BioSciences, Inc.	06/30/2021	59584013801	Candin Skin Test Antigen liquid 1U/0.1mL 1.0mL	04/01/2021	18.00	243.00	None	Single Source Drug	22942	None	When pricing its products Nielsen takes into consideration multiple factors - including but not limited to: research and development (or asset acquisition) investments including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts fees and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends including inflation rates; the clinical and economic value of the product; and overall corporate business goals.	None	None	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000420	Nielsen BioSciences, Inc.	06/30/2021	59584014001	Spherusol Skin Test Antigen liquid 1.27mg/0.1mL 1.0mL	05/01/2021	68.00	918.00	None	Single Source Drug	1818	None	When pricing its products Nielsen takes into consideration multiple factors - including but not limited to: research and development (or asset acquisition) investments including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts fees and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends including inflation rates; the clinical and economic value of the product; and overall corporate business goals.	None	None	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000204	Noden Pharma USA, Inc.	03/31/2021	70839015030	TEKTURNA 150MG TAB 30/EA	01/15/2021	20.20	244.62	02/19/2026	Innovator Multiple Source Drug	0	1	None	1	None	1	07/01/2016	Novartis	None	1	None	150.19	136.66	2011	81.98	None	Acquired less than 5 years ago - WAC at intro to market was by NVS
Rx0000204	Noden Pharma USA, Inc.	03/31/2021	70839030030	TEKTURNA 300MG TAB 30/EA	01/15/2021	25.48	308.61	02/19/2026	Innovator Multiple Source Drug	0	1	None	1	None	1	07/01/2016	Novartis	None	1	None	189.48	172.41	2011	103.42	None	Acquired less than 5 years ago - WAC at intro to market was by NVS
Rx0000204	Noden Pharma USA, Inc.	03/31/2021	70839011230	TEKTURNA HCT 150/12.5MG TAB 30/EA	01/15/2021	20.20	244.62	07/13/2028	Single Source Drug	0	1	None	1	None	1	07/01/2016	Novartis	None	1	None	150.19	136.66	2011	81.98	None	Acquired less than 5 years ago - WAC at intro to market was by NVS
Rx0000204	Noden Pharma USA, Inc.	03/31/2021	70839012530	TEKTURNA HCT 150/25MG TAB 30/EA	01/15/2021	20.20	244.62	07/13/2028	Single Source Drug	0	1	None	1	None	1	07/01/2016	Novartis	None	1	None	150.19	136.66	2011	81.98	None	Acquired less than 5 years ago - WAC at intro to market was by NVS
Rx0000204	Noden Pharma USA, Inc.	03/31/2021	70839031230	TEKTURNA HCT 300/12.5MG TAB 30/EA	01/15/2021	25.48	308.61	07/13/2028	Single Source Drug	0	1	None	1	None	1	07/01/2016	Novartis	None	1	None	189.48	172.41	2011	103.42	None	Acquired less than 5 years ago - WAC at intro to market was by NVS
Rx0000204	Noden Pharma USA, Inc.	03/31/2021	70839032530	TEKTURNA HCT 300/25MG TAB 30/EA	01/15/2021	25.48	308.61	07/13/2028	Single Source Drug	0	1	None	1	None	1	07/01/2016	Novartis	None	1	None	189.48	172.41	2011	103.42	None	Acquired less than 5 years ago - WAC at intro to market was by NVS
Rx0000073	Novartis	03/31/2021	00065027510	Azopt 1% Drops 10mL, 10pk, 1 dropper bottle	01/06/2021	17.89	343.23	07/02/2017	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Product was on the market at the time of the acquisition. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2021	00065027515	Azopt 1% Drops 15mL, 15pk, 1 dropper bottle	01/06/2021	26.84	514.80	07/02/2017	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Product was on the market at the time of the acquisition. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2021	00078063968	Cosentyx 150mg/ml, pen, 1 Sensoready Pen	01/06/2021	387.90	5929.33	05/05/2033	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2021	00078063941	Cosentyx 150mg/ml, pen, 2 Sensoready Pens	01/06/2021	387.90	5929.33	05/05/2033	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2021	00078063997	Cosentyx 150mg/ml, syringe, 1 Syringe	01/06/2021	387.90	5929.33	05/05/2033	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2021	00078063998	Cosentyx 150mg/ml, syringe, 2 Syringes	01/06/2021	387.90	5929.33	05/05/2033	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2021	00065924007	DUREZOL 0.05% 5mL, Drops, 5pk, 1 dropper bottle	01/06/2021	10.82	207.62	11/18/2019	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2021	00078065967	Entresto 24/26mg - Tabs, 180 Each Bottle, 1 bottle	01/06/2021	114.40	1748.68	08/22/2033	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2021	00078065920	Entresto 24/26mg - Tabs, 60 Each Bottle, 1 bottle	01/06/2021	38.13	582.89	08/22/2033	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2021	00078077767	Entresto 49/51mg - Tabs, 180 Each Bottle, 1 bottle	01/06/2021	114.40	1748.68	08/22/2033	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2021	00078077720	Entresto 49/51mg - Tabs, 60 Each Bottle, 1 bottle	01/06/2021	38.13	582.89	08/22/2033	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2021	00078069667	Entresto 97/103mg - Tabs, 180 Each Bottle, 1 bottle	01/06/2021	114.40	1748.68	08/22/2033	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2021	00078069620	Entresto 97/103mg - Tabs, 60 Each Bottle, 1 bottle	01/06/2021	38.13	582.89	08/22/2033	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2021	00065175014	Ilevro 0.3%, Drops, 3mL per bottle, 1 bottle	01/06/2021	15.96	306.17	03/31/2032	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Product was on the market at the time of the acquisition. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2021	00078086001	KISQALI 200mg daily dose, 1 blister pack x 21 tablets (21 tablets per carton)	01/06/2021	370.81	5668.15	04/14/2036	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2021	00078086742	KISQALI 400mg daily dose, 3 blister packs x 14 tablets (42 tablets per carton)	01/06/2021	741.63	11336.34	04/14/2036	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2021	00078087463	KISQALI 600mg daily dose, 3 blister packs x 21 tablets (63 tablets per carton)	01/06/2021	927.04	14170.42	04/14/2036	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2021	00078090961	KISQALI FEMARA CO-PACK, Kisqali 1 blister pack, containing 21 tablets 200mg per tablet, Femara 2.5mg 28s	01/06/2021	370.81	5668.15	04/14/2036	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2021	00078091661	KISQALI FEMARA CO-PACK, Kisqali 3 blister packs, containing 14 tablets (200mg per tablet) (400mg daily	01/06/2021	741.63	11336.34	04/14/2036	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2021	00078092361	KISQALI FEMARA CO-PACK, Kisqali 3 blister packs, containing 21 tablets (200mg per tablet) (600mg daily dose), Femara 2.5mg 28s	01/06/2021	927.04	14170.42	04/14/2036	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2021	00078066615	Mekinist 0.5 mg 30 tabs per bottle, 1 bottle	01/06/2021	193.01	3702.29	01/28/2032	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2021	00078066815	Mekinist 2 mg 30 tabs per bottle, 1 bottle	01/06/2021	656.91	12600.79	01/28/2032	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2021	00078068415	Promacta 12.5 mg, 30 tabs per bottle, 1 bottle	01/06/2021	368.99	5640.31	02/01/2028	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2021	00078068515	Promacta 25 mg, 30 tabs per bottle, 1 bottle	01/06/2021	368.99	5640.31	02/01/2028	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2021	00078068615	Promacta 50 mg, 30 tabs per bottle, 1 bottle	01/06/2021	667.76	10207.17	02/01/2028	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2021	00078068715	Promacta 75 mg, 30 tabs per bottle, 1 bottle	01/06/2021	1001.64	15310.76	02/01/2028	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2021	00078069819	Rydapt 25 mg, 112 tabs per bottle, 1 bottle	01/06/2021	986.52	18923.27	12/02/2030	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	NDC 00078-0698-02 and 00078-0698-51 are not commercially available. The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2021	00078069899	Rydapt 25 mg, 56 tabs per bottle, 1 bottle	01/06/2021	493.26	9461.64	12/02/2030	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	NDC 00078-0698-02 and 00078-0698-51 are not commercially available. The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2021	00065414727	SIMBRINZA 1% / 0.2%, Drops, 8mL per bottle, 1 bottle	01/06/2021	9.44	181.12	10/30/2030	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Product was on the market at the time of the acquisition. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2021	00078068266	Tafinlar 50 mg, 120 tabs per bottle, 1 bottle	01/06/2021	469.48	9005.53	10/15/2030	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2021	00078068166	Tafinlar 75 mg, 120 tabs per bottle, 1 bottle	01/06/2021	605.05	11605.88	10/15/2030	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2021	00078059287	Tasigna 150mg, 28 capsule per bottle, 4 bottles	01/06/2021	1030.12	15746.14	10/07/2032	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2021	00078052687	Tasigna 200mg, 28 capsule per bottle, 4 bottles	01/06/2021	1030.12	15746.14	10/07/2032	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2021	00078095166	Tasigna 50mg, 120 capsule per bottle, 1 bottle	01/06/2021	1103.70	16870.81	10/07/2032	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2021	00078067066	Votrient 200 mg 120 tabs per bottle, 1 bottle	01/06/2021	758.88	14556.72	10/19/2023	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2021	00078091112	XIIDRA 5% 50 mg/mL 60-count carton, 12 pouches of 5 single-use containers (0.2mL each)	01/06/2021	38.75	592.29	07/25/2033	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	05/09/2019	Takeda Pharmaceutical Company Limited	3400000000	None	Novartis will pay $3.4 billion upfront, plus potential milestone payments of up to $1.9 billion.	553.54	2019.00	2016	426.73	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000033	Novo	03/31/2021	00169770521	Norditropin FlexPro Subcutaneous Solution Pen-injector 10 MG/1.5ML - 1 syringe in 1 carton	01/15/2021	65.34	1398.74	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Norditropin is no longer under patent. NNI is the original manufacturer of Norditropin and did not acquire the product from a different company.
Rx0000033	Novo	03/31/2021	00169770821	Norditropin FlexPro Subcutaneous Solution Pen-injector 15 MG/1.5ML - 1 syringe in 1 carton	01/15/2021	98.00	2098.10	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Norditropin is no longer under patent. NNI is the original manufacturer of Norditropin and did not acquire the product from a different company.
Rx0000033	Novo	03/31/2021	00169770321	Norditropin FlexPro Subcutaneous Solution Pen-injector 30 MG/3ML - 1 syringe in 1 carton	01/15/2021	196.01	4196.21	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Norditropin is no longer under patent. NNI is the original manufacturer of Norditropin and did not acquire the product from a different company.
Rx0000033	Novo	03/31/2021	00169770421	Norditropin FlexPro Subcutaneous Solution Pen-injector 5 MG/1.5ML - 1 syringe in 1 carton	01/15/2021	32.67	699.37	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Norditropin is no longer under patent. NNI is the original manufacturer of Norditropin and did not acquire the product from a different company.
Rx0000033	Novo	03/31/2021	00169413212	Ozempic (0.25 or 0.5 MG/DOSE) Subcutaneous Solution Pen-injector 2 MG/1.5ML - 1 syringe in 1 carton	01/15/2021	40.55	851.60	06/21/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	NNI holds a number of patents related to Ozempic and has included the expiration date for Patent #10335462 which is the patent with the latest expiry date in the FDA Orange Book. NNI is the original manufacturer of Ozempic and did not acquire the product from a different company.
Rx0000033	Novo	03/31/2021	00169413602	Ozempic (1 MG/DOSE) Subcutaneous Solution Pen-injector 2 MG/1.5ML - 2 syringes in 1 carton	01/15/2021	40.55	851.60	06/21/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	NNI holds a number of patents related to Ozempic and has included the expiration date for Patent #10335462 which is the patent with the latest expiry date in the FDA Orange Book. NNI is the original manufacturer of Ozempic and did not acquire the product from a different company.
Rx0000033	Novo	03/31/2021	00169406013	Victoza Subcutaneous Solution Pen-injector 6mg/mL 3x3mL - 3 syringes in 1 carton	01/15/2021	48.39	1016.25	07/09/2037	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	NNI holds a number of patents related to Victoza. We included the expiration date for Patent #9968659 which is the patent with the latest expiry date in the FDA Orange Book. NNI is the original manufacturer of Victoza and did not acquire the product from a different company.
Rx0000033	Novo	03/31/2021	00169406012	Victoza Subcutaneous Solution Pen-injector Victoza 6mg/mL 2x3mL - 2 syringes in 1 carton	01/15/2021	32.26	677.50	07/09/2037	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	NNI holds a number of patents related to Victoza. We included the expiration date for Patent #9968659 which is the patent with the latest expiry date in the FDA Orange Book. NNI is the original manufacturer of Victoza and did not acquire the product from a different company.